Evaluation of multiple serum markers in advanced melanoma
Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S, Martín-Algarra S, González A.
Laboratory of Biochemistry, University Clinic of Navarra, Avd. Pio XII 36, Pamplona, 31008, Spain.
Revista: Tumour Biology
Fecha: 01/08/2011Oncología Médica Bioquímica Clínica
The aim of this retrospective study was to analyse in advanced melanoma the potential tumor markers S-100B, melanoma inhibiting activity protein (MIA) and YKL-40 compared to LDH. Serum levels of S-100B, MIA, LDH and YKL-40 were measured in 110 patients with advanced melanoma (36 in stage IIIB/C and 74 in stage IV), in 66 disease-free patients and in 65 healthy controls. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. The combination of S-100B plus MIA had the best diagnostic sensitivity, and the addition of LDH did not further increase this sensitivity. MIA was an independent prognostic factor of overall survival. Patients with both S-100B and MIA elevated had a significant shorter survival than those with both S-100B and MIA under the cut-off. YKL-40 levels did not differentiate patients with advanced melanoma from controls. We concluded that the combination of MIA plus S-100B showed a better prognostic value in advanced melanoma compared to LDH.
CITA DEL ARTÍCULO Tumour Biol. 2011 Dec;32(6):1155-61. Epub 2011 Aug 20.
tal vezLE INTERESE
La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.
Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.
Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.